Galectin Therapeutics
在场
Galectin Therapeutics 是一家在股票代码 GALT (US) 下上市的公司。
高管
查看带有其 19 名主要高管的组织结构图
Galectin Therapeutics 搜索最多的简介
- Joel Lewis, President, Chief Executive Officer and Director
- Kevin Freeman, Vice Chairman of the Board
- Kary Eldred, Director
高管在Galectin Therapeutics变化
- Khurram Jamil 曾任 Vice President, Clinical Development, 现升职为 Chief Medical Officer (新闻发布的2024八月2号).
- Khurram Jamil已作为Vice President, Clinical Development加入公司 (新闻发布的2024三月13号).
创建提醒
跟踪 Galectin Therapeutics 的高管变动
生物技术
Galectin Therapeutics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Galectin Therapeutics 的最新新闻稿
- Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 | Galectin Therapeutics Inc.
- Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress | Galectin Therapeutics Inc.
- Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer | Galectin Therapeutics Inc.
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update | Galectin Therapeutics Inc.
- View more press releases Close
通过电子邮件
